PremiumMarket NewsBlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO11h agoBMYJPM
PremiumCompany AnnouncementsBristol-Myers Squibb Tracks Real-World Use of Luspatercept in Anemia Care14h agoBMY
PremiumRatingsMorgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook18h agoNVS
Morgan Stanley’s Graham Parry Reiterates Buy on Novartis, Citing Pelacarsen Upside and Above‑Consensus EPS Outlook